Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to -$22.1 million.

  • BIO-TECHNE's Change in Accured Expenses fell 102.56% to -$22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 75.97%. This contributed to the annual value of $15.4 million for FY2025, which is 40.21% down from last year.
  • As of Q3 2025, BIO-TECHNE's Change in Accured Expenses stood at -$22.1 million, which was down 749.65% from $3.4 million recorded in Q2 2025.
  • BIO-TECHNE's 5-year Change in Accured Expenses high stood at $21.6 million for Q1 2022, and its period low was -$28.4 million during Q3 2022.
  • For the 3-year period, BIO-TECHNE's Change in Accured Expenses averaged around $2.5 million, with its median value being $3.4 million (2025).
  • In the last 5 years, BIO-TECHNE's Change in Accured Expenses soared by 2,049.68% in 2021 and then plummeted by 304.86% in 2024.
  • Over the past 5 years, BIO-TECHNE's Change in Accured Expenses (Quarterly) stood at $8.5 million in 2021, then crashed by 157.54% to -$4.9 million in 2022, then soared by 264.67% to $8.1 million in 2023, then spiked by 83.15% to $14.8 million in 2024, then plummeted by 102.56% to -$22.1 million in 2025.
  • Its Change in Accured Expenses was -$22.1 million in Q3 2025, compared to $3.4 million in Q2 2025 and $8.1 million in Q1 2025.